- Efficacy and safety of Cialis across ethnic groups and various risk factors in men with erectile dysfunction Use of a novel noninferiority study design
- Effect of chronic Cialis administration on penile hypoxia induced by cavernous neurotomy in the rat
- Structural elucidation of a Cialis analogue found as an adulterant of a herbal product
- Gateways to clinical trials
- Phosphodiesterase 5 in the female pig and human urethra morphological and functional aspects
- 'Sex for life' Men's counter-stories on 'erectile dysfunction' male sexuality and ageing
- Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation
- Treatment strategy for "non-responders" to Cialis and vardenafil a real-life study
- Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime
- Treatment of erectile dysfunction after nerve-preserving radical retropubic prostatectomy]
- Gateways to clinical trials
- Circulating endothelial progenitor cells and endothelial function after chronic Cialis treatment in subjects with erectile dysfunction
- Erectile dysfunction following radical retropubic prostatectomy epidemiology pathophysiology and pharmacological management
- Efficacy of oral Cialis a new long-acting phosphodiesterase-5 inhibitor for the short-term treatment of pulmonary arterial hypertension in a dog
- Testosterone and erectile function in hypogonadal men unresponsive to Cialis results from an open-label uncontrolled study
- PDE5 inhibitors are there differences
- Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with Cialis
- Cialis pharmacokinetics in healthy subjects
- Drug Insight oral phosphodiesterase type 5 inhibitors for erectile dysfunction
- Erectile dysfunction
- Application of LC-ESI-MS-MS for detection of synthetic adulterants in herbal remedies
- Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction
- Efficacy and safety of on-demand oral Cialis in the treatment of men with erectile dysfunction in Taiwan a randomized double-blind parallel placebo-controlled clinical study
- Determining the earliest time within 30 minutes to erectogenic effect after Cialis 10 and 20 mg a multicenter randomized double-blind placebo-controlled at-home study
- Update on clinical trials of Cialis demonstrates no increased risk of cardiovascular adverse events
- Review of phosphodiesterases in the urogenital system new directions for therapeutic intervention
- Efficacy and safety of daily Cialis in men with erectile dysfunction previously unresponsive to on-demand Cialis
- Comparison of efficacy safety and tolerability of on-demand Cialis and daily dosed Cialis for the treatment of erectile dysfunction
- The efficacy of Cialis in clinical populations
- Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction
- Efficacy and safety of oral Cialis in the treatment of men in Canada with erectile dysfunction a randomized double-blind parallel placebo-controlled clinical trial
- Sexual intercourse attempt patterns with two dosing regimens of Cialis in men with erectile dysfunction results from the SURE study in 14 European countries
- Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction
- Platelet count and function at high altitude and in high-altitude pulmonary edema
- Phosphodiesterase type 5 is not upregulated by Cialis in cultures of human penile cells
- The second Princeton consensus on sexual dysfunction and cardiac risk new guidelines for sexual medicine
- Gateways to clinical trials
- Phosphodiesterase 11 a brief review of structure expression and function
- Sexual dysfunction and cardiac risk the Second Princeton Consensus Conference
- Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension
- Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors focus on alpha-blocker interactions
- Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors
- Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors
- Phosphodiesterase type 5 inhibitors molecular pharmacology and interactions with other phosphodiesterases
- Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle interaction with nitric oxide
- Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression
- Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography-electrospray ionization tandem mass spectrometry
- Gateways to clinical trials
- Indirect comparison of interventions using published randomised trials systematic review of PDE-5 inhibitors for erectile dysfunction
- Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy is there a cause and effect relationship
Cialis Soft Tab
Generic Cialis Soft Tabs 20 Mg is a medicine containing the active substance Cialis. It is available as tablets (2.5, 5, 10 and 20 mg).